Sigilon Therapeutics, Inc.

SGTX · NASDAQ
Analyze with AI
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Activities
Net Income-$43,561-$77,311-$54,608-$43,925
Dep. & Amort.$1,264$1,118$854$675
Deferred Tax$0$3-$854$207
Stock-Based Comp.$5,901$6,149$3,127$2,073
Change in WC-$19,267-$13,420-$2,547-$10,890
Other Non-Cash$4,189$5,056-$7,620$1,786
Operating Cash Flow-$51,474-$78,405-$61,648-$50,074
Investing Activities
PP&E Inv.-$537-$1,834-$972-$1,209
Net Acquisitions$0$0$0$0
Inv. Purchases-$42,524-$16,226$0$0
Inv. Sales/Matur.$30,750$0$0$0
Other Inv. Act.$230$0$0$0
Investing Cash Flow-$12,081-$18,060-$972-$1,209
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$61-$622$132,527$0
Stock Repurch.$0-$622$51,723$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$1,606$1,554$189,397$63,242
Financing Cash Flow-$1,606$1,554$189,397$63,242
Forex Effect$0$0$0$0
Net Chg. in Cash-$65,161-$94,911$126,777$11,959
Supplemental Information
Beg. Cash$108,511$203,422$76,645$64,686
End Cash$43,350$108,511$203,422$76,645
Free Cash Flow-$52,011-$80,239-$62,620-$51,283